Last reviewed · How we verify
NCT05390619
Different Doses of vPDT in the Treatment of cCSC
NA trial testing 50% dose of photodynamic therapy in Central Serous Chorioretinopathy in 100 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- 50% dose of photodynamic therapy
- 70% dose of photodynamic therapy
Conditions studied
- Central Serous Chorioretinopathy — all drugs for Central Serous Chorioretinopathy →
- Therapy, Photodynamic — all drugs for Therapy, Photodynamic →
Sponsor
Peking University People's Hospital
Who can join
Adults 18 to 75, any sex, with Central Serous Chorioretinopathy or Therapy, Photodynamic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment group. The primary treatment success rate and adverse event rate of the two groups were compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for chronic CSC was summarized.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05390619
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Central Serous Chorioretinopathy
Currently open trials in the same condition.
- NCT06527326 — the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy · NA · recruiting
- NCT06346405 — Central Serous Chorioretinopathy and Micropulse Laser Treatment · recruiting
- NCT05570591 — Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy · NA · recruiting
- NCT05589974 — Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05390619 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 25 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05390619.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing